Trial · NCT06072482
Registered outcomes20
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 20
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs) | Up to Month 60 | |
| Primary | Percentage of Participants Experiencing Adverse Events of Special Interest | Up to Month 60 | |
| Primary | Percentage of Participants Experiencing Serious Adverse Events | Up to Month 60 | |
| Primary | Percentage of Participants Experiencing Adverse Events Leading to Withdrawal | Up to Month 60 | |
| Primary | Percentage of Participants Experiencing Adverse Events Leading to Death | Up to Month 60 | |
| Primary | Number of Participants Experiencing Clinical Significant Changes from Baseline in Vital Signs Measurements | Up to Month 60 | |
| Primary | Number of Participants Experiencing Clinical Significant Changes from Baseline in Hematology Assessments | Up to Month 60 | |
| Primary | Number of Participants Experiencing Clinical Significant Changes from Baseline in Serum Chemistry Assessments | Up to Month 60 | |
| Primary | Number of Participants Experiencing Clinical Significant Changes from Baseline in Urinalysis Assessments | Up to Month 60 | |
| Secondary | Group A and B Participants who Achieved Remission at Month 12: Time to Relapse in AAV Between Month 12 and Month 60 | Month 12 to Month 60 | |
| Secondary | Group A and B Participants who Achieved Remission at Month 12: Percentage of Participants who Relapse After Achieving Remission at Month 12 | Month 12 to Month 60 | |
| Secondary | Groups A and C: Percentage of Participants who Achieved Sustained Remission at Month 60 | Month 60 | |
| Secondary | Group A and C Participants with Overt Renal Disease at Baseline: Change from Baseline to Month 60 in Estimated Glomerular Filtration Rate (eGFR) | Baseline and Month 60 | |
| Secondary | Groups A and C: Change from Baseline to Month 60 in Short Form 36 Health Survey Version 2 (SF-36 v2) General Health Perception Score | Baseline and Month 60 | |
| Secondary | Groups A and C: Change from Baseline to Month 60 in EuroQoL-5 Dimension 5 Levels (EQ-5D-5L) Visual Analogue Scale (VAS) | Baseline and Month 60 | |
| Secondary | Percentage of Participants who Achieved Remission at Month 6 | Month 6 | |
| Secondary | Groups A and C: Change from Baseline to Month 60 in Vasculitis Damage Index (VDI) | Baseline and Month 60 | |
| Secondary | Groups A and C: Percentage of Participants with Composite Outcome of Initiation of Maintenance Dialysis, Kidney Transplantation, or Death | Up to Month 60 | |
| Secondary | Percentage of Participants With Glucocorticoid Use | Up to Month 60 | |
| Secondary | Percentage of Participants With Immunosuppressant Use | Up to Month 60 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06072482/registered